AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Oncternal Therapeutics to Present at Stifel Healthcare Conference

November 11, 2019

SAN DIEGO--(BUSINESS WIRE)--Nov 11, 2019--

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.

A live webcast of the presentation will be available online via a link from the investor relations page of the Company’s website at www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005083/en/

CONTACT: Investors

Richard Vincent

858-434-1113

rvincent@oncternal.comMedia

Jason Spark

619-849-6005

jason@canalecomm.com

KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Oncternal Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/11/2019 08:00 AM/DISC: 11/11/2019 08:01 AM

http://www.businesswire.com/news/home/20191111005083/en